Replies to post #131859 on Biotech Values

[iwfal]

Thanks. Some questions:

In some emerging markets, FoB penetration is much higher than in Europe due to weak patent protection and/or lax approval standards.

Well, clearly the generics makers aren't hoping for US FoB markets like those in developing countries - so I still do not understand why the generics makers care much at all about non-sub biosimilars. All told it looks like, perhaps, $4-8B spread over 10's of generic manufacturers in 6 or 7 years. ($4-8B may sound like a lot but is perhaps 10% of the expected value of the US traditional generics market in the same timeframe) Some possible reason they might care(?):

1) They expect it to evolve to substitutible as the technology matures (they just don't think it is there yet)?

2) The vocal biosimilar companies are just a few - and they care because they believe biosimilars are more difficult than other generics so the competition will be less?

3) ...